Article
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
JAMA - 10 Apr 2013
Xing Mingzhao, Alzahrani Ali S, Carson Kathryn A, Viola David, Elisei Rossella, Bendlova Bela, Yip Linwah, Mian Caterina, Vianello Federica, Tuttle R Michael, Robenshtok Eyal, Fagin James A, Puxeddu Efisio, Fugazzola Laura, Czarniecka Agnieszka, Jarzab Barbara, O'Neill Christine J, Sywak Mark S, Lam Alfred K, Riesco-Eizaguirre Garcilaso, Santisteban Pilar, Nakayama Hirotaka, Tufano Ralph P, Pai Sara I, Zeiger Martha A, Westra William H, Clark Douglas P, Clifton-Bligh Roderick, Sidransky David, Ladenson Paul W, Sykorova Vlasta
Abstract excerpt
IMPORTANCE: BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-related patient mortality has not been established. OBJECTIVE: To investigate the relationship between BRAF V600E mutation and PTC-related mortality. DESIGN, SETTING, AND PARTICIPANTS: Retrospective study of 1849 patients (1411 women and 438 men) with a median age of 46 years (interquartile range, 34-58 years)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.